CTC Spray/Cyclo Spray

Main information

  • Trade name:
  • CTC spray
  • Pharmaceutical form:
  • Cutaneous spray, solution
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • CTC spray
    Germany
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Tetracycline and derivatives
  • Therapeutic area:
  • Cattle Food, Pigs Food

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • NL/V/0104/001
  • Authorization date:
  • 23-06-2011
  • EU code:
  • NL/V/0104/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

CTCSPRAY,2.45%w/wforcattle,sheepandpigs

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Percontainerof270ml:

ActiveSubstance:

ChlortetracyclineHCl.

Theactiveingredientcontentis2.45%w/w(equivalentto3.210g)

Excipients:

PatentBlueV(E131) 0.15%w/w(equivalentto0,196g)

Butane100 68.77%w/w(equivalentto89,920g)

Percontainerof520ml:

ActiveSubstance:

ChlortetracyclineHCl.

Theactiveingredientcontentis2.45%w/w(equivalentto6.420g)

Excipients:

PatentBlueV(E131) 0.15%w/w(equivalentto0,392g)

Butane100 68.77%w/w(equivalentto179.840g)

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

CutaneousSpray,Suspension

4. CLINICALPARTICULARS

4.1 Targetspecies

Cattle,sheepandpigs.

4.2 Indicationsforuse,specifyingthetargetspecies

Treatmentofsuperficialtraumaticorsurgicalwoundscontaminatedwithchlortetracycline-sensitive

agents.

Theproductcanbeusedaspartofatreatmentforsuperficialskinandclaw/hoofinfections,in

particularinterdigitaldermatitis(footrotandfoulinthefoot)anddigitaldermatitiscausedbymicro-

organismssensitivetochlortetracycline.

4.3 Contraindications

Donotuseincaseofhypersensitivitytotetracyclinesortootheringredientsoftheproduct.Donotuse

ontheudderoflactatinganimalsifmilkisintendedforhumanconsumption.

4.4 Specialwarningsforeachtargetspecies

None.

4.5 Specialprecautionsforuse

Specialprecautionsforuseinanimals

Protecttheeyeswhensprayinginthevicinityofthehead.Cleantheaffectedareathoroughlybefore

spraying.Afteradministrationontheclaw/hooftheanimalshouldbekeptonadrygroundatleastfor

anhourstime.Useoftheproductshouldbebasedonsusceptibilitytestingofthebacteriaisolatedfrom

theanimal.Ifthisisnotpossible,therapyshouldbebasedonlocal(regional,farmlevel)epidemiological

informationaboutsusceptibilityofthetargetbacteria.Useoftheproductdeviatingfromtheinstructions

givenintheSPCmayincreasetheprevalenceofbacteriaresistanttochlortetracyclineandmay

decreasetheeffectivenessoftreatmentwithothertetracyclines,duetothepotentialforcross

resistance.

Specialprecautionstobetakenbythepersonadministeringtheveterinarymedicinal

producttoanimals

Becauseoftheriskofsensitisationandcontactdermatitis,skincontactshouldbeavoided.

Wearappropriateimpermeablegloveswhilsthandlingtheproduct.

Becauseofriskofeyeirritation,contactwiththeeyesshouldbeavoided.Protecttheeyesand

face.

Donotsprayonanakedflameoranyincandescentmaterial.

Donotpierceorburn,evenafteruse.

Avoidinhalingvapours.Applytheproductinopenairorinsufficientlyventilatedarea.

Washhandsafteruse.

Donoteatorsmokewhilstadministeringtheproduct.

4.6 Adversereactions(frequencyandseriousness)

Hypersensitivityreactionsmayoccurrarely.

4.7 Useduringpregnancy,lactationorlay

Followingcutaneousadministrationoftheproduct,chlortetracyclineisnotabsorbed,norexcretedwith

themilk.Therefore,theproductissafeforuseduringpregnancyandlactation.

4.8 Interactionwithothermedicinalproductsandotherformsofinteraction

Aftercutaneousadministrationofchlortetracyclinespray,chlortetracyclineisnotabsorbed.Parenteral

ororaladministeredantibioticswillnotpenetratethedermis.Thereforenointeractionsaretobe

expected.

Nodataoninteractionswithotherlocaltreatmentsareavailable.

4.9 Amountstobeadministeredandadministrationroute

Theproductisindicatedforcutaneousadministration.Shakethecontainerthoroughlybeforespraying.

Thecontainershouldbeheldatadistanceofapproximately15-20cmfromtheareatobesprayed;

sprayfor3secondsuntilthetreatment-areaisevenlycoloured.

Incaseofclaw/hoofinfectionsthistreatmentshouldberepeatedafter30seconds.

Fortreatmentofsuperficialtraumaticorsurgicalwoundscontaminatedwithchlortetracycline-

sensitiveagentsasingleadministrationisrecommended.

FortreatmentofDermatitisDigitalisadministrationtwicewitha30secondintervalduringthree

consecutivedaysonceortwicedailyisrecommended.

Fortreatmentofotherclaw/hoofinfections(footrotandfoulinthefoot),administrationtwicewitha30

secondintervalonceortwicedailyisrecommended.Dependentontheseriousnessoftheinjuryand

therateofimprovementtreatmentshouldberepeatedwithin1to3days.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Notapplicable.

4.11Withdrawalperiod(s)

Meat :zerodays

Milk :zerodays

Seealso4.3contraindications

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:tetracyclineantibiotics.

ATCvetcode:QD06A

5.1 Pharmacodynamicproperties

Invitro,chlortetracyclineisprimarilybacteriostatic.Chlortetracyclineexertsitsactionbyinhibitingthe

proteinsynthesisofthebacterialcell.Especiallycell-divisionandtheformationofthecellwallare

impaired.Chlortetracyclinebindstoreceptorsonthe30S-subunitofthebacterialribosomewherethey

interferewiththebindingoftheaminoacyl-transferRNAtotheacceptorsiteonthemessengerRNA

ribosomecomplex.

5.2 Pharmacokineticparticulars

Followingcutaneousadministrationofchlortetracyclinespray,chlortetracyclineabsorptionisnegligible.

Thereforetheproductwillonlyhavealocaleffect,nosystemiceffectsaretobeanticipated.

6. PHARMACEUTICALPARTICULARS

6.1 Listofexcipients

Colloidalanhydroussilica

Isopropylalcohol

PatentblueV(E-131)

Sorbitantriolate

Butane100

6.2 Incompatibilities

Notapplicable.

6.3 Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:3years.

6.4.Specialprecautionsforstorage

Pressurizedcontainer.Donotexposethecontainertodirectsunlightortotemperatureshigherthan

50°C.Keepawayfromsourcesofignition.

6.5 Natureandcompositionofimmediatepackaging

270mlpressurisedcontainerofcoatedtinplatewithaplasticvalvemechanismandsprayingnozzle.

520mlpressurisedcontainerofcoatedtinplatewithaplasticvalvemechanismandsprayingnozzle.

6.6 Specialprecautionsforthedisposalofunusedveterinarymedicinalproductorwaste

materialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuchveterinarymedicinal

productsshouldbedisposedofinaccordancewithlocalrequirements.

7. MARKETINGAUTHORISATIONHOLDER

EurovetAnimalHealthB.V.

Handelsweg25,POBox179,5530ADBladel

TheNetherlands

8. MARKETINGAUTHORISATIONNUMBER(S)

9. DATEOFRENEWALOFTHEAUTHORISATION

20-03-2009

10 DATEOFREVISIONOFTHETEXT

May2011

Methodofretailsaleorsupply

PrescriptionOnlyMedicine

LABELLING

PARTICULARSTOAPPEARONTHEIMMEDIATEPACKAGE

Spraywhichcanonlyspraystraightup

Thefulltextwillbeprintedonthecontainer

1. NAMEANDADDRESSOFTHEMARKETINGAUTHORISATIONHOLDERAND

OFTHEMANUFACTURINGAUTHORISATIONHOLDERRESPONSIBLEFOR

BATCHRELEASE,IFDIFFERENT

MarketingauthorisationholderandManufacturerforthebatchrelease:

EurovetAnimalHealthB.V.

Handelsweg25,POBox179,5530ADBladel

TheNetherlands

2. NAMEOFTHEVETERINARYMEDICINALPRODUCT

CTCSPRAY,2.45%w/wforcattle,sheepandpigs

3. STATEMENTOFTHEACTIVESUBSTANCE(S)ANDOTHERINGREDIENT(S)

Percontainerof270ml:

ActiveSubstance:

ChlortetracyclineHCl.

Theactiveingredientcontentis2.45%w/w(equivalentto3.210g)

Excipients:

PatentBlueV(E131) 0.15%w/w(equivalentto0,196g)

Butane100 68.77%w/w(equivalentto89,920g)

Percontainerof520ml:

ActiveSubstance:

ChlortetracyclineHCl.

Theactiveingredientcontentis2.45%w/w(equivalentto6.420g)

Excipients:

PatentBlueV(E131) 0.15%w/w(equivalentto0,392g)

Butane100 68.77%w/w(equivalentto179.840g)

4. INDICATION(S)

Treatmentofsuperficialtraumaticorsurgicalwoundscontaminatedwithchlortetracycline-sensitive

agents.

Theproductcanbeusedaspartofatreatmentforsuperficialskinandclaw/hoofinfections,in

particularinterdigitaldermatitis(footrotandfoulinthefoot)anddigitaldermatitiscausedbymicro-

organismssensitivetochlortetracycline.

5. CONTRAINDICATIONS

Donotuseincaseofhypersensitivitytotetracyclinesortootheringredientsoftheproduct.Donotuse

ontheudderoflactatinganimalsifmilkisintendedforhumanconsumption.

6. ADVERSEREACTIONS

Hypersensitivityreactionsmayoccurrarely.Ifyounoticeanyseriouseffectsorothereffectsnot

mentionedinthisleaflet,pleaseinformyourveterinarysurgeon.

7. TARGETSPECIES

Cattle,sheepandpigs.

8. DOSAGEFOREACHSPECIES,ROUTE(S)ANDMETHODOF

ADMINISTRATION

Theproductisindicatedforcutaneousadministration.Shakethecontainerthoroughlybeforespraying.

Thecontainershouldbeheldatadistanceofapproximately15-20cmfromtheareatobesprayed;

sprayfor3secondsuntilthetreatment-areaisevenlycoloured.

Incaseofclaw/hoofinfectionsthistreatmentshouldberepeatedafter30seconds.

Fortreatmentofsuperficialtraumaticorsurgicalwoundscontaminatedwithchlortetracycline-

sensitiveagentsasingleadministrationisrecommended.

FortreatmentofDermatitisDigitalisadministrationtwicewitha30secondintervalduringthree

consecutivedaysonceortwicedailyisrecommended.

Fortreatmentofotherclaw/hoofinfections(footrotandfoulinthefoot),administrationtwicewitha30

secondintervalonceortwicedailyisrecommended.Dependentontheseriousnessoftheinjuryand

therateofimprovementtreatmentshouldberepeatedwithin1to3days.

9. ADVICEONCORRECTADMINISTRATION

--

10. WITHDRAWALPERIOD

Meat :zerodays

Milk :zerodays

Seealsocontraindications.

11. SPECIALSTORAGEPRECAUTIONS

Keepoutofthereachandsightofchildren.

Pressurizedcontainer.Donotexposethecontainertodirectsunlightortotemperatureshigherthan

50°C.Keepawayfromsourcesofignition.

12. SPECIALWARNING(S)

Specialprecautionforuseinanimals

Protecttheeyeswhensprayinginthevicinityofthehead.Cleantheaffectedareathoroughlybefore

spraying.Afteradministrationontheclaw/hooftheanimalshouldbekeptonadrygroundatleastfor

anhourstime.Useoftheproductshouldbebasedonsusceptibilitytestingofthebacteriaisolatedfrom

theanimal.Ifthisisnotpossible,therapyshouldbebasedonlocal(regional,farmlevel)epidemiological

informationaboutsusceptibilityofthetargetbacteria.Useoftheproductdeviatingfromtheinstructions

givenintheSPCmayincreasetheprevalenceofbacteriaresistanttochlortetracyclineandmay

decreasetheeffectivenessoftreatmentwithothertetracyclines,duetothepotentialforcross

resistance.

Specialprecautionstobetakenbythepersonadministeringtheveterinarymedicinal

producttoanimals

Becauseoftheriskofsensitisationandcontactdermatitis,skincontactshouldbeavoided.

Wearappropriateimpermeablegloveswhilsthandlingtheproduct.

Becauseofriskofeyeirritation,contactwiththeeyesshouldbeavoided.Protecttheeyesandface.

Donotsprayonanakedflameoranyincandescentmaterial.

Donotpierceorburn,evenafteruse.

Avoidinhalingvapours.Applytheproductinopenairorinsufficientlyventilatedarea.

Washhandsafteruse.

Donoteatorsmokewhilstadministeringtheproduct.

Hypersensitivityreactionsmayoccurrarely.

Useduringpregnancyorlactation

Followingcutaneousadministrationoftheproduct,chlortetracyclineisnotabsorbed,norexcretedwith

themilk.Therefore,theproductissafeforuseduringpregnancyandlactation.

Interactionwithothermedicinalproducts

Aftercutaneousadministrationofchlortetracyclinespray,chlortetracyclineisnotabsorbed.Parenteral

ororaladministeredantibioticswillnotpenetratethedermis.Thereforenointeractionsaretobe

expected.

Nodataoninteractionswithotherlocaltreatmentsareavailable.

13. SPECIALPRECAUTIONSFORTHEDISPOSALOFUNUSEDPRODUCTOR

WASTEMATERIALS,IFANY

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuchveterinarymedicinal

productsshouldbedisposedofinaccordancewithlocalrequirements.

14. DATEONWHICHTHEPACKAGELEAFLETWASLASTAPPROVED

May2011

15. OTHERINFORMATION

Methodofretailsaleorsupply

PrescriptionOnlyMedicine

PARTICULARSTOAPPEARONTHEIMMEDIATEPACKAGE

Spraywhichcanspraystraightupandinverted

Thefulltextwillbeprintedonthecontainer

1. NAMEANDADDRESSOFTHEMARKETINGAUTHORISATIONHOLDERAND

OFTHEMANUFACTURINGAUTHORISATIONHOLDERRESPONSIBLEFOR

BATCHRELEASE,IFDIFFERENT

MarketingauthorisationholderandManufacturerforthebatchrelease:

EurovetAnimalHealthB.V.

Handelsweg25,POBox179,5530ADBladel

TheNetherlands

2. NAMEOFTHEVETERINARYMEDICINALPRODUCT

CTCSPRAY,2.45%w/wforcattle,sheepandpigs

3. STATEMENTOFTHEACTIVESUBSTANCE(S)ANDOTHERINGREDIENT(S)

Percontainerof270ml:

ActiveSubstance:

ChlortetracyclineHCl.

Theactiveingredientcontentis2.45%w/w(equivalentto3.210g)

Excipients:

PatentBlueV(E131) 0.15%w/w(equivalentto0,196g)

Butane100 68.77%w/w(equivalentto89,920g)

Percontainerof520ml:

ActiveSubstance:

ChlortetracyclineHCl.

Theactiveingredientcontentis2.45%w/w(equivalentto6.420g)

Excipients:

PatentBlueV(E131) 0.15%w/w(equivalentto0,392g)

Butane100 68.77%w/w(equivalentto179.840g)

4. INDICATION(S)

Treatmentofsuperficialtraumaticorsurgicalwoundscontaminatedwithchlortetracycline-sensitive

agents.

Theproductcanbeusedaspartofatreatmentforsuperficialskinandclaw/hoofinfections,in

particularinterdigitaldermatitis(footrotandfoulinthefoot)anddigitaldermatitiscausedbymicro-

organismssensitivetochlortetracycline.

5. CONTRAINDICATIONS

Donotuseincaseofhypersensitivitytotetracyclinesortootheringredientsoftheproduct.Donotuse

ontheudderoflactatinganimalsifmilkisintendedforhumanconsumption.

6. ADVERSEREACTIONS

Hypersensitivityreactionsmayoccurrarely.Ifyounoticeanyseriouseffectsorothereffectsnot

mentionedinthisleaflet,pleaseinformyourveterinarysurgeon.

7. TARGETSPECIES

Cattle,sheepandpigs.

8. DOSAGEFOREACHSPECIES,ROUTE(S)ANDMETHODOF

ADMINISTRATION

Theproductisindicatedforcutaneousadministration.Shakethecontainerthoroughlybeforespraying.

Thecontainershouldbeheldatadistanceofapproximately15-20cmfromtheareatobesprayed;

sprayfor3secondsuntilthetreatment-areaisevenlycoloured.

Incaseofclaw/hoofinfectionsthistreatmentshouldberepeatedafter30seconds.

Fortreatmentofsuperficialtraumaticorsurgicalwoundscontaminatedwithchlortetracycline-

sensitiveagentsasingleadministrationisrecommended.

FortreatmentofDermatitisDigitalisadministrationtwicewitha30secondintervalduringthree

consecutivedaysonceortwicedailyisrecommended.

Fortreatmentofotherclaw/hoofinfections(footrotandfoulinthefoot),administrationtwicewitha30

secondintervalonceortwicedailyisrecommended.Dependentontheseriousnessoftheinjuryand

therateofimprovementtreatmentshouldberepeatedwithin1to3days.

9. ADVICEONCORRECTADMINISTRATION

--

10. WITHDRAWALPERIOD

Meat :zerodays

Milk :zerodays

Seealsocontraindications.

11. SPECIALSTORAGEPRECAUTIONS

Keepoutofthereachandsightofchildren.

Pressurizedcontainer.Donotexposethecontainertodirectsunlightortotemperatureshigherthan

50°C.Keepawayfromsourcesofignition.

12. SPECIALWARNING(S)

Specialprecautionforuseinanimals

Protecttheeyeswhensprayinginthevicinityofthehead.Cleantheaffectedareathoroughlybefore

spraying.Afteradministrationontheclaw/hooftheanimalshouldbekeptonadrygroundatleastfor

anhourstime.Useoftheproductshouldbebasedonsusceptibilitytestingofthebacteriaisolatedfrom

theanimal.Ifthisisnotpossible,therapyshouldbebasedonlocal(regional,farmlevel)epidemiological

informationaboutsusceptibilityofthetargetbacteria.Useoftheproductdeviatingfromtheinstructions

givenintheSPCmayincreasetheprevalenceofbacteriaresistanttochlortetracyclineandmay

decreasetheeffectivenessoftreatmentwithothertetracyclines,duetothepotentialforcross

resistance.

Specialprecautionstobetakenbythepersonadministeringtheveterinarymedicinal

producttoanimals

Becauseoftheriskofsensitisationandcontactdermatitis,skincontactshouldbeavoided.

Wearappropriateimpermeablegloveswhilsthandlingtheproduct.

Becauseofriskofeyeirritation,contactwiththeeyesshouldbeavoided.Protecttheeyesandface.

Donotsprayonanakedflameoranyincandescentmaterial.

Donotpierceorburn,evenafteruse.

Avoidinhalingvapours.Applytheproductinopenairorinsufficientlyventilatedarea.

Washhandsafteruse.

Donoteatorsmokewhilstadministeringtheproduct.

Hypersensitivityreactionsmayoccurrarely.

Useduringpregnancyorlactation

Followingcutaneousadministrationoftheproduct,chlortetracyclineisnotabsorbed,norexcretedwith

themilk.Therefore,theproductissafeforuseduringpregnancyandlactation.

Interactionwithothermedicinalproducts

Aftercutaneousadministrationofchlortetracyclinespray,chlortetracyclineisnotabsorbed.Parenteral

ororaladministeredantibioticswillnotpenetratethedermis.Thereforenointeractionsaretobe

expected.

Nodataoninteractionswithotherlocaltreatmentsareavailable.

13. SPECIALPRECAUTIONSFORTHEDISPOSALOFUNUSEDPRODUCTOR

WASTEMATERIALS,IFANY

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuchveterinarymedicinal

productsshouldbedisposedofinaccordancewithlocalrequirements.

14. DATEONWHICHTHEPACKAGELEAFLETWASLASTAPPROVED

May2011

15. OTHERINFORMATION

Methodofretailsaleorsupply

PrescriptionOnlyMedicine

Symbolswillbeplacedonthelabeltextpresentedonthecan

10-10-2018

Sprayology Issues Voluntary Nationwide Recall of Homeopathic Aqueous-Based Medicines Due to Microbial Contamination

Sprayology Issues Voluntary Nationwide Recall of Homeopathic Aqueous-Based Medicines Due to Microbial Contamination

Eight and Company LLC, d/b/a Sprayology is voluntarily recalling all lots within expiry from 10/18-7/22 of its aqueous-based homeopathic product line for human use. All products manufactured by the contract manufacturer, King Bio, have been recalled due to possible microbial contamination.

FDA - U.S. Food and Drug Administration

31-5-2018

Fluticasone Propionate Nasal Spray by Apotex Corp: Recall - Due to Potential for Small Glass Particles

Fluticasone Propionate Nasal Spray by Apotex Corp: Recall - Due to Potential for Small Glass Particles

The glass particles could block the actuator and impact the functionality of the pump and expose patients to the glass particles.

FDA - U.S. Food and Drug Administration

31-5-2018

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. is voluntarily recalling one (1) lot of Fluticasone Propionate Nasal Spray, USP, 50 mcg per spray, 120 Metered Sprays, to the consumer level. The Fluticasone Propionate Nasal Spray USP 50 mcg per spray 120 Metered Sprays has been found to contain small glass particles. The glass particles could block the actuator and impact the functionality of the pump. The issue was discovered through a customer complaint.

FDA - U.S. Food and Drug Administration

25-5-2018

Safe use of personal insect repellents

Safe use of personal insect repellents

While enjoying the warm summer weather, don't forget to protect yourself from pesky bugs that bite! Health Canada is reminding Canadians to use bug spray and other insect repellents safely to avoid mosquito and other bug bites.

Health Canada

21-5-2018

Homeopathic Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir by MBI Distributing: Recall - Due to a Lack of Adequate Controls

Homeopathic Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir by MBI Distributing: Recall - Due to a Lack of Adequate Controls

Manufacturing products without proper process controls increases the probability that products will vary in strength, quality and purity

FDA - U.S. Food and Drug Administration

18-5-2018

MBI Distributing, Inc. Issues Voluntary Nationwide Recall of Homeopathic Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir Due to a Lack of Process Controls

MBI Distributing, Inc. Issues Voluntary Nationwide Recall of Homeopathic Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir Due to a Lack of Process Controls

MBI Distributing, Inc. is voluntarily recalling all lots of homeopathic Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir, within expiry, to the consumer level. The drug products have been found to be manufactured with a lack of adequate controls.

FDA - U.S. Food and Drug Administration

21-11-2018

EU/3/18/2082 (Takeda Pharma A/S)

EU/3/18/2082 (Takeda Pharma A/S)

EU/3/18/2082 (Active substance: 5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride) - Orphan designation - Commission Decision (2018)7791 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/040/18

Europe -DG Health and Food Safety

29-6-2018

EU/3/18/2028 (BioCryst UK Ltd)

EU/3/18/2028 (BioCryst UK Ltd)

EU/3/18/2028 (Active substance: (R)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride) - Orphan designation - Commission Decision (2018)4173 of Fri, 29 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/003/18

Europe -DG Health and Food Safety

10-5-2018

Inhalation and nasal spray registered medicines

Inhalation and nasal spray registered medicines

New information about application pathways and data requirements for inhalation and nasal spray registered medicines

Therapeutic Goods Administration - Australia